Mike Bromley

Prof. Mike Bromley


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2022 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
MFMatthew C. Fisher
Matthew C. Fisher
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
JBJudith Berman
Judith Berman
TBTihana Bicanic
Tihana Bicanic
EBElaine Bignell
Elaine Bignell
PVPaul Verweij
Paul Verweij

27 March 2015 in Science
Verified
Journal Article
Closed access
PDF file
DDDavid W. Denning
David W. Denning
MBMike Bromley
Mike Bromley
Few drugs are coming to market, but opportunities for drug development exist

10 April 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MFMarcin G. Fraczek
Marcin G. Fraczek
MBMike Bromley
Mike Bromley
ABAhmed Buied
Ahmed Buied
CMCaroline B. Moore
Caroline B. Moore
RRRanjith Rajendran
Ranjith Rajendran
PBPaul Bowyer
Paul Bowyer
Recent increases in triazole resistance in Aspergillus fumigatus have been attributed primarily to target site (cyp51A) mutations. A recent survey of resistant isolates in Manchester showed that >50% of resistant isolates had no mutation in cyp51A or its promoter. We investigated the mechanisms of resistance in clinical azole-resistant isolates without cyp51A mutations. Twelve azole-resistant isolates, 10 of which were itraconazole resistant, were studied. Bioinformatic comparisons between Candida albicans efflux genes and A. fumigatus genome data identified 20 putative azole transporter genes. Basal and azole-induced expression of these genes and cyp51A was quantified using RT–PCR with comparison with clinical azole-susceptible isolates. Function of high basal or itraconazole-induced expression transporters was tested by gene knockout in azole-susceptible and azole-resistant isolates. All susceptible strains showed minimal basal expression of cdr1B compared with 8 of 10 azole-resistant strains with high basal expression of this gene (>5-fold), 3 of which showed >30-fold increased expression. Knockout of this gene resulted in a 4-fold reduction in itraconazole, posaconazole and voriconazole MICs for a susceptible clinical isolate and a 4-fold reduction in itraconazole susceptibility in a clinical resistant isolate. One strain showed a >500-fold induction of cyp51A. No increase in basal expression or expression after induction was seen for the 18 remaining putative transporters. The reasons behind the shift away from target site mutation in azole-resistant isolates from Manchester are unknown. The modest change in expression of cdr1B in azole-susceptible strains implies that only study of resistant isolates will lead to further understanding of resistance mechanisms in A. fumigatus.

25 April 2022 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
Johanna RhodesJohanna Rhodes
Johanna Rhodes
AAAlireza Abdolrasouli
Alireza Abdolrasouli
KDKatie Dunne
Katie Dunne
TSThomas R. Sewell
Thomas R. Sewell
YZYuyi Zhang
Yuyi Zhang
MFMatthew C. Fisher
Matthew C. Fisher
Infections caused by the fungal pathogenAspergillus fumigatusare increasingly resistant to first-line azole antifungal drugs. However, despite its clinical importance, little is known about how susceptible patients acquire infection from drug-resistant genotypes in the environment. Here, we present a population genomic analysis of 218A. fumigatusisolates from across the UK and Ireland (comprising 153 clinical isolates from 143 patients and 65 environmental isolates). First, phylogenomic analysis shows strong genetic structuring into two clades (A and B) with little interclade recombination and the majority of environmental azole resistance found within clade A. Second, we show occurrences where azole-resistant isolates of near-identical genotypes were obtained from both environmental and clinical sources, indicating with high confidence the infection of patients with resistant isolates transmitted from the environment. Third, genome-wide scans identified selective sweeps across multiple regions indicating a polygenic basis to the trait in some genetic backgrounds. These signatures of positive selection are seen for loci containing the canonical genes encoding fungicide resistance in the ergosterol biosynthetic pathway, while other regions under selection have no defined function. Lastly, pan-genome analysis identified genes linked to azole resistance and previously unknown resistance mechanisms. Understanding the environmental drivers and genetic basis of evolving fungal drug resistance needs urgent attention, especially in light of increasing numbers of patients with severe viral respiratory tract infections who are susceptible to opportunistic fungal superinfections.

25 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JOJason Oliver
Jason Oliver
GSGraham E. M. Sibley
Graham E. M. Sibley
NBNicola Beckmann
Nicola Beckmann
KDKatharine S. Dobb
Katharine S. Dobb
MSMartin J. Slater
Martin J. Slater
MBMike Birch
Mike Birch
There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 µg/mL—greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals.

12 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NGNeil Gow
Neil Gow
CJCarolyn Johnson
Carolyn Johnson
JBJudith Berman
Judith Berman
ACAlix T Coste
Alix T Coste
Christina CuomoChristina Cuomo
Christina Cuomo
KEKeegan Edgar
Keegan Edgar
Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global health care priority. Some analyses, including the O’Neill report, have predicted that deaths due to drug-resistant bacterial infections may eclipse the total number of cancer deaths by 2050. Although fungal infections remain in the shadow of public awareness, total attributable annual deaths are similar to, or exceeds, global mortalities due to malaria, tuberculosis or HIV. The impact of fungal infections has been exacerbated by the steady rise of antifungal drug resistant strains and species which reflects the widespread use of antifungals for prophylaxis and therapy, and in the case of azole resistance inAspergillus, has been linked to the widespread agricultural use of antifungals. This review, based on a workshop hosted by the Medical Research Council and the University of Exeter, illuminates the problem of antifungal resistance and suggests how this growing threat might be mitigated.